Skip to main content

Advertisement

SpringerLink
Log in

Novel technologies for improving the safety and efficacy of CAR-T cell therapy

  • Progress in Hematology
  • Immunotherapy: Cancer immunotherapy development: From a different perspective
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Chimeric antigen receptor-T (CAR-T) cell therapy has shown significant therapeutic efficacy in the treatment of hematological B-cell malignancies. However, the efficacy of CAR-T cell therapy against solid tumors is limited due to the heterogeneity of tumor antigens and the immunosuppressive tumor microenvironment. Therefore, there is strong demand for novel technologies to improve the efficacy of CAR-T cell therapy. In addition, as CAR-T cells often cause severe side effects, systems to control the activity of CAR-T cells so as to avoid or lessen the occurrence and intensity of these side effects are needed. Here, we describe recently emerging approaches to enhance and/or regulate CAR-T cell functions. These approaches have led to the development of CAR-T therapies with improved efficacy and safety, which are expected to be clinically applied to a variety of cancer types in combination with other therapies, such as immune checkpoint inhibitors, chemotherapy, molecular targeted drugs, and radiation therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor modified T cells in chronic lymphoid leukemia. NEngl J Med. 2011;365:725–33. https://doi.org/10.1056/NEJMoa1103849.

    Article  CAS  Google Scholar 

  2. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439–48. https://doi.org/10.1056/NEJMoa1709866.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Grant SJ, Rosko AE, Giri S, et al. Clinical presentation, risk factors, and outcomes of immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T cell therapy: a systematic review. Transplant Cell Ther. 2022;28(6):294–302.

    Article  CAS  PubMed  Google Scholar 

  5. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18:843–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Labanieh L, Majzner RG, Mackall CL. Programming CAR-T cells to kill cancer. Nat Biomed Eng. 2018;2:377–91.

    Article  CAS  PubMed  Google Scholar 

  7. Batra SA, Rathi P, Guo L, Bulsara S, et al. Glypican-3-specific CAR T cells co-expressing IL15 and IL21 have superior expansion and antitumor activity against hepatocellular carcinoma. Cancer Immunol Res. 2020;8(3):309–20.

    Article  CAS  PubMed  Google Scholar 

  8. Hu B, Ren J, June CH, et al. Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18. Cell Rep. 2017;20:3025–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Pegram HJ, Lee JC, Brentjens RJ, et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood. 2012;119:4133–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Liu Y, Di S, Jiang H, et al. Armored inducible expression of IL-12 enhances antitumor activity of glypican-3-targeted chimeric antigen receptor-engineered T cells in hepatocellular carcinoma. J Immunol. 2019;203:198–207.

    Article  CAS  PubMed  Google Scholar 

  11. Tamada K, Geng D, Sakoda Y, Bansal N, Srivastava R, Li Z, Davila E. Redirecting gene-modified T cells toward various cancer types using tagged antibodies. Clin Cancer Res. 2012;18(23):6436–45.

    Article  CAS  PubMed  Google Scholar 

  12. Urbanska K, Lanitis E, Kelderman S, et al. A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor. Cancer Res. 2012;72:1844–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Cho JH, Collins JJ, Wong WW. Universal chimeric antigen receptors for multiplexed and logical control of T cell responses. Cell. 2018;173(6):1426–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Rodgers DT, Kim CH, Young TS, et al. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. Proc Natl Acad Sci USA. 2016;113(4):E459–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. John LB, Devaud C, Duong CPM, et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res. 2013;19:5636–46.

    Article  CAS  PubMed  Google Scholar 

  16. Choi BD, Carter BS, Maus MV, et al. CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma. J Immunother Cancer. 2019;7:304.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Suarez ER, Chang DK, Marasco WA, et al. Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model. Oncotarget. 2016;7:34341–55.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Rafiq S, Miele MM, Li Z, et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol. 2018;36:847–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Nakajima M, Nagano H, Tamada K, et al. Improved survival of chimeric antigen receptor-engineered T (CAR-T) and tumor-specific T cells caused by anti-programmed cell death protein 1 single-chain variable fragment-producing CAR T cells. Cancer Sci. 2019;110:3079–88.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Narayan V, Fraietta JA, Haas NB, et al. PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nature Med. 2022;28:724–34.

    Article  CAS  PubMed  Google Scholar 

  21. Adachi K, Sakoda Y, Tamada K, et al. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat Biotechnol. 2018;36:346–51.

    Article  CAS  PubMed  Google Scholar 

  22. Di Stasi A, Tey SK, Grilley B, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011;365:1673–83.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Tiberghien P, Ferrand C, Deconinck E, et al. Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T cell-depleted allogeneic marrow graft. Blood. 2001;97:63–72.

    Article  CAS  PubMed  Google Scholar 

  24. Griffioen M, van Egmond EHM, Kester MGD, Willemze R, Falkenburg JHF, Heemskerk MHM. Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy. Haematologica. 2009;94:1316–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Wang X, Chang W-C, Ostberg JR, et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood. 2011;118:1255–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Paszkiewicz PJ, Fräßle SP, Drexler I, et al. Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia. J Clin Invest. 2016;126:4262–72.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Sakemura R, Terakura S, Miyao K, et al. A Tet-On inducible system for controlling CD19-chimeric antigen receptor expression upon drug administration. Cancer Immunol Res. 2016;4:658–68.

    Article  CAS  PubMed  Google Scholar 

  28. Zimmermann K, Abken H, Schambach A, et al. Design and characterization of an “all-in-one” lentiviral vector system combining constitutive anti-G(D2) CAR expression and inducible cytokines. Cancers. 2020;12:375.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Roybal KT, Park JS, Lim WA. Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell. 2016;164:770–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Wilkie S, van Schalkwyk MC, Maher J, et al. Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J Clin Immunol. 2012;32:1059–70.

    Article  CAS  PubMed  Google Scholar 

  31. Fedorov VD, Themeli M, Sadelain M, et al. PD-1–and CTLA-4–based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med. 2013;5:215ra172.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Immunology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan

    Keisuke Ohta, Yukimi Sakoda & Koji Tamada

Authors
  1. Keisuke Ohta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yukimi Sakoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Koji Tamada
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Keisuke Ohta.

Ethics declarations

Conflict of interest

KT and YS is shareholder at Noile-Immune Biotech Inc., and receive remuneration from Noile-Immune Biotech Inc.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ohta, K., Sakoda, Y. & Tamada, K. Novel technologies for improving the safety and efficacy of CAR-T cell therapy. Int J Hematol 117, 647–651 (2023). https://doi.org/10.1007/s12185-022-03478-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-022-03478-7

Keywords

Search

Navigation